Urinary tract infections (UTIs) are among the most prevalent bacterial infections in the community, affecting about 150 million people globally. Ladies, in particular, are susceptible to UTIs, with nearly 20-30% of women with an UTI
experiencing recurrence. Other high-risk groups include pregnant mothers, children, elderly patients, especially those with indwelling catheters and neuropathic bladder.
Cranberries (Vaccinium macrocarpon) in a form of juice or tablets have been widely used or self-administered for prevention of UTI. However, its efficacy remains controversial, mainly attributed to the lack of standardisation and large variations in the Proanthocyanidin (PAC) concentration in these products.
PAC, particularly the A-type, is the only recognised compound that could interfere with bacterial adhesion in the urinary tract. Cranberry consumption with sufficient A-type PAC can cause an anti-adhesion response in urine. When bacteria are unable to adhere to cells, they cannot grow and cause infection.
- Existing urinary conditions such as urinary incontinence
- Lack of water intake
- Sexually active
- Uncontrolled / poorly controlled diabetes
- Long-term use of bladder catheters
Oximacro® is manufactured by an Italian company called Biosfered S.r.l. Biosfered was founded in 2013 is an Academic Spin Off of the University of Turin with a team of academic experience of university researchers.
Oximacro® is produced using only high quality extracts of cranberry, and it goes through the proprietary Bisofered process to obtain a purified and concentrated PACs-A cranberry extract. The levels of PACs-A is quantified using BL-DMAC, a method used for validating cranberry UTI claims in the EU.
Clinically Proven! Work in 7 days!
Oximacro® has been researched for its anti-UTI and anti-virus properties. In one published study in Urology Journal, to determine the efficacy of Oximacro® in UTI prevention in female and male. After 7 days, the active group showed 80% recovered cases, while the placebo was unable to recover from UTI. Eventually, all placebo volunteers had to be treated with antibiotic to reduce pain. The count of bacteria in the urine and bladder was significantly lower in Oximacro® treated volunteers compared with placebo volunteers. The researcher’s concluded that the use of dosages must base on PACs-A and 72 mg PACs–A was found to be was found to be highly effective to prevent UTI.
Each vegetable capsule (400mg) contains:
Vaccinium macrocarpon (cranberry) fruit extract 120mg
(Standardized to contain 36.72mg A-Type PAC)
Take 1 capsule once daily after meal.